Sodium Stibogluconate

Sodium Stibogluconate is antiprotozoal, used in the treatment of all types of leishmaniasis along with other drugs (eg; pentamidine and amphotericin B).

Brands
STIBOTIM
Adult Dose
Dose: 8.57 mg/kg
Single Dose: 8.6 (8.57)
Frequency: 24 hourly
Route: IM
Instructions: For 7-10 Days
Neonatal
Dose: 10 mg/kg
Single Dose: 10 (10)
Frequency: 24 hourly
Route: Intra Muscular
Instructions: -
Paedriatic
Dose: 10 mg/kg
Single Dose: 10 (10)
Frequency: 24 hourly
Route: Intra Muscular
Instructions: -
Characteristics
belongs to Antimonic Acid. It belongs to Antiparasitic pharmacological group on the basis of mechanism of action and also classified in Antiparasitic pharmacological group.The Molecular Weight of Sodium Stibogluconate is 392.80. Its pKa is Acidic.
Contraindications
Sodium Stibogluconate is contraindicated in conditions like Renal diseases,Pneumonia,Liver diseases,Heart disease,Complicating secondary infection,Previous antimonial therapy.
Effects
The severe or irreversible adverse effects of Sodium Stibogluconate, which give rise to further complications include Venous thrombosis.Sodium Stibogluconate produces potentially life-threatening effects which include Hepatotoxicity, Cardiotoxicity, Renal toxicity. which are responsible for the discontinuation of Sodium Stibogluconate therapy.The signs and symptoms that are produced after the acute overdosage of Sodium Stibogluconate include Renal failure, Circulatory collapse, Disseminated intravascular coagulopathy.The symptomatic adverse reactions produced by Sodium Stibogluconate are more or less tolerable and if they become severe, they can be treated symptomatically, these include Anorexia, Myalgia, Malaise, Arthralgia, Nausea and vomiting.
Indications
Sodium Stibogluconate is primarily indicated in conditions like Leishmaniasis, Visceral leishmaniasis.
Interactions
No data regarding the interactions of Sodium Stibogluconate was found.
Interfrence
Risks
Drug should not be given to Pregnant Mothers, Cardiac / Hypertensive Patients, patients suffering from Kidney dysfunction, Geriatrics, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.
Storage
IV Inj, IM Inj Store Below 25°C. Protect from Sunlight.
Warnings
Safety of the sodium stibogluconate has not been determined in pregnant women , in the children
Back to List

Any information that appears on this website page is provided for the purpose of general information. This website has been compiled in good faith by HMIS.Online. However, no guarantee is made as to the completeness, validity or accuracy of the information it contains.